HGB levels may influence the apparent Vd of the drug by reflecting the patient’s anemic status (where anemia may be accompanied by fluid retention) and circulating blood volume (such as chronic blood loss caused by portal hypertension in liver cirrhosis). This evidence concerns the gene CYGB and portal hypertension.